Whalesbook
So, Canara HSBC Life Insurance ka FY26 Q4 result thoda mix raha. Ek taraf VNB mein jabardast growth hui, wahi dusri taraf APE expectation se kam raha.
Asal mein hua yeh hai ki, Canara HSBC Life ka Value of New Business (VNB) ekdum rockstar ki tarah 48.7% badh kar ₹2.1 billion ho gaya hai. Yeh market ki expectations se bhi 21.4% zyada hai! Iska credit jaata hai protection business ko (+96.1% YoY), non-par savings ko (+43.4%), aur annuity products ko (+24.7%).
Lekin, picture thoda confusing hai kyunki Annualized Premium Equivalent (APE) pichhle quarter se 29.8% neeche gir kar ₹700 crore par aa gaya hai. YoY growth 12.0% hai, jo theek hai, par QoQ drop kaafi bada hai. Iska main reason hai Unit Linked Insurance Plans (ULIPs) mein 31.9% ki kami.
Is mixed performance ko dekh kar, Systematix jaise brokerage ne apna 'Buy' rating toh maintain kiya hai, par price target ko ₹190 se ghatakar ₹180 kar diya hai. Unka kehna hai ki stock apne embedded value ke 1.7x par trade kar raha hai FY28 ke liye.
Stock khud bhi thoda confusing chal raha hai. Pichhle ek mahine mein 1.35% gira hai, par 6 mahine mein 14.96% bhaga hai. Company ka naya agency channel abhi shuruati stage mein hai aur 6 mahine mein ₹14 crore APE collect kar chuka hai, jo ek positive sign hai.
Baaki companies ki baat karein toh ICICI Prudential Life ka profit 61.95% badha hai, jabki SBI Life ka profit 1.09% gira hai aur HDFC Life ka profit 4% badha hai. Overall, Indian life insurance sector FY26 mein 15.7% grow kiya hai, jo FY25 ke 5.1% growth se kaafi achha hai.
Sabse bada risk hai APE ka girna aur company ka valuation. Iska P/E ratio 107-115x hai, jo SBI Life (76x) aur HDFC Life (71x) se kaafi upar hai. Full year FY26 VNB margin 22.4% raha, jo SBI Life (27.5%) se kam hai. Management ko is gap ko fill karne ke liye consistent growth dikhani padegi.
Management ka kehna hai ki FY26 mein VNB 41% badh kar ₹627 crore raha hai aur margin 22.4% hai. Woh bancassurance aur agency network ko use karke growth continue karna chahte hain. ULIPs mein kami ko cover karna aur high valuation ko justify karna hi unka main focus rahega.